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Abstract
Uterine sarcomas are a rare group of neoplasms with aggressive clinical course and poor prognosis.
They are classified into four main histological subtypes in order of decreasing incidence:
carcinosarcomas, leiomyosarcomas, endometrial stromal sarcomas and "other" sarcomas. The
pathological subtype demands a tailored approach. Surgical resection is regarded as the mainstay
of treatment. Total abdominal hysterectomy and bilateral salpingo-oophorectomy represents the
standard treatment of uterine sarcomas. Pelvic and para-aortic lymph node dissection in
carcinosarcomas is recommended, given their high incidence of lymph node metastases, and may
have a role in endometrial stromal sarcomas. Adjuvant radiation therapy has historically been of
little survival value, but it appears to improve local control and may delay recurrence. Regarding
adjuvant chemotherapy, there is little evidence in the literature supporting its use except for
carcinosarcomas. However, more trials are needed to address these issues, especially, their
sequential application. Patients with uterine sarcomas should be referred to large academic centers
for participation in clinical trials.
Background
Uterine sarcomas are rare neoplasms comprising 1% of all
gynaecologic malignancies and 4–9% of all malignant
uterine neoplasms [1,2]. It is estimated that the incidence
of uterine sarcomas varies between 0.5 and 3.3 cases per
100.000 females per year [3]. Uterine sarcomas usually
display aggressive clinical behaviour, with a great ten-
dency to local recurrence and even greater to distant
spread [4-7]. Due to their low incidence and the fact that
they lack a preinvasive stage, there is no established prac-
tice for screening these tumours. The rarity of uterine sar-
comas and their often aggressive clinical course has
resulted in a relatively limited amount of literature.
The staging of uterine sarcomas is based on the Interna-
tional Federation of Gynecology and Obstetrics staging
system for uterine corpus cancer. According to WHO clas-
sification, uterine sarcomas are classified into four main
histological subtypes in order of decreasing incidence: car-
cinocarcomas, leiomyosarcomas, endometrial stromal
sarcomas and "other" sarcomas [8]. Unfortunately, clini-
cal-trial reports and literature reviews often include a
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broad range of histological subtypes of sarcoma, which
restricts interpretation and application of results.
Response rates from protocols with multiple subtypes
should consequently be interpreted with caution. There-
fore, the effort to tailor the approach to patients with uter-
ine sarcomas by pathological subtype seems mandatory.
Carcinosarcomas (CSs)
Epidemiology and Tumour Features
Carcinosarcomas represent a highly aggressive subtype of
uterine malignancy [9-12]. CSs comprise both malignant
epithelial and malignant sarcomatous components [13-
15]. The differentiation of the epithelial component is
usually glandular with the endometrioid adenocarcinoma
being the most common epithelial type. The mesenchy-
mal components may be "homologous", similar to tissues
normally present in the uterus, or "heterologous," resem-
bling tissue foreign to the uterus [12-15]. Patients with
CSs usually present with a bulky polypoid mass extending
into and even through the endocervical canal [16,17].
The recurrence rate for stage I and II CSs is approximately
50% [12,18]. Unfortunately, patients who present with
early-stage disease confined to the uterus have a 2- to 5-year
overall survival of approximately 50% (reviewed by Kan-
jeekal et al [19]). Factors associated with poor prognosis
include stage, high grade of tumour, adnexal spread and
lymph node metastasis. The prognostic relevance of his-
topathological variables, the grade of sarcomatous and epi-
thelial component, the mitotic count of sarcomatous
component, as well as the depth of myometrial invasion, the
lymph-vascular space involvement and peritoneal cytology
have been implicated in some studies as significant patho-
logic predictors [10,11,20-23]. It should, however, be noted
that these findings did not emerge in the majority of studies
conducted. Notwithstanding, the limited number of patients
and the fact that most studies are not stratified for stage do
not allow definitive conclusions to be drawn.
Surgical Treatment
Surgical treatment of CSs should comprise exploratory
laparotomy, total abdominal hysterectomy (TAH), bilat-
eral salpingo-oophorectomy (BSO), omentectomy, aspi-
ration of abdominal fluid for cytologic evaluation, pelvic
and para-aortic lymph node dissection and tumor debulk-
ing at the time of presentation [12,13,16,17,19,24].
Lymph node dissection is indicated for CSs given their
high incidence of lymph node metastases [18,25,26].
Moreover, the number of lymph nodes collected in stage
I-II patients, who underwent pelvic and para-aortic lymph
node sampling, has been correlated with the risk of recur-
rence and survival [25,26]. Surgical debulking in patients
with uterine CSs should be attempted, given that patients
with minimal residual disease may have a longer survival
than those left with gross residual disease after surgical
debulking [12]. More accurate surgical staging of CSs, as
with endometrial cancer, may allow physicians to better
assess the need for adjuvant treatment.
Radiation Therapy
Historically, treatment for uterine CSs has included adju-
vant pelvic radiation therapy with or without brachyther-
apy [12]. Until 2007, no well-controlled, randomized
studies had been published, and most reports were based
on small non-randomized trials [26-28]. The best conclu-
sion that could be drawn from these reports was that the
routine place of adjuvant pelvic radiation was limited as it
only led to a statistically significant reduction of recur-
rences within the radiation field, but did not confer to
overall survival [26-29]. Nonetheless, adjuvant radiother-
apy has been shown to improve survival for patients with
early-stage CSs who had not undergone lymph node dis-
section [29,30].
In their retrospective analysis, Callister et al [31] found that
patients treated with pelvic irradiation had a lower rate of
pelvic recurrence than those treated with surgery alone
(28% versus 48%, p = 0.0002), but the 5-year overall sur-
vival and distant metastasis rates were not significantly dif-
ferent. Interestingly, patients treated with pelvic irradiation
had a longer median time to any distant relapse (17.3 ver-
sus. 7.0 months, p = 0.001) than those treated with surgery
alone. In another retrospective analysis of 2461 women
with uterine CSs within the SEER (Surveillance, Epidemiol-
ogy, and End results program) database of the US National
Cancer Institute, radiation therapy predicted an improved
overall and disease specific survival [32]. Five-year overall
survival rates were 41.5% and 33.2% (p < 0.001) for
women receiving or not irradiation, respectively. More ana-
lytically, women with stage I-III disease experienced a ben-
efit in overall survival (hazard ratio = 0.87, p = 0.03), while
those with stage IV disease experienced benefit in both
overall (HR = 0.63, p < 0.001) and uterine-specific survival
(HR = 0.63, p = 0.004).
In 2007, GOG published the results of a randomized phase
III study which compared patient outcome following treat-
ment with adjuvant whole abdominal irradiation (WAI)
versus chemotherapy with three cycles of cisplatin and ifos-
famide (CIM) for patients with CS. Eligible patients had
stage I-IV disease, no more than 1 cm postsurgical resid-
uum and/or no extra-abdominal spread. FIGO stage was
I+II in 44% of the enrolled, eligible women. Adjusting for
stage and age, the recurrence rate was 21% lower for CIM
patients than for WAI patients (relative hazard = 0.789, p =
0.245). The estimated death rate was 29% lower among the
CIM group (relative hazard = 0.712, p = 0.085). Although
the observed differences were not statistically significant,
the authors seems to favor the use of combination chemo-
therapy in future trials [33].World Journal of Surgical Oncology 2009, 7:38 http://www.wjso.com/content/7/1/38
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In the mid-1980s, the European Organisation for
Research and Treatment of Cancer (EORTC) Gynaecolog-
ical Cancer Group proposed a trial to evaluate adjuvant
radiotherapy in stage I+II uterine sarcomas (protocol
55874). The study opened in 1987 taking 13 years to
accrue 224 patients and its results were first published in
2008. Patients were required to have undergone as a min-
imum, TAH and BSO and washings, but nodal sampling
was optional. There were 103 LMSs, 91 CSs and 28 ESSs.
Patients were randomised to either observation or pelvic
radiation, 51 Gy in 28 fractions over 5 weeks. Analysis for
all patients revealed a reduction in local relapse (p =
0.004), but no effect on either OS or PFS. Furthermore, no
difference in either overall or disease-free survival was
demonstrated among CS patients but there was an
increased local control for those receiving radiation, while
this benefit was not observed for women with LMSs. Prog-
nostic factor analysis showed that stage, age and histolog-
ical subtype were important predictors of behaviour [34].
In conclusion, CSs appears to behave like poorly differenti-
ated endometrial carcinomas. Offering adjuvant pelvic
radiation applies only to patients that have not undergone
a complete surgical staging including lymph node staging.
However, further randomized trials are necessary in order
to clarify the exact role of adjuvant radiotherapy, especially
in combination with platinum-based chemotherapy.
Chemotherapy
The role of adjuvant chemotherapy in CSs is still under
debate. In a prospective phase II GOG study, patients with
completely resected stage I or II CSs received three cycles of
adjuvant chemotherapy with ifosfamide and cisplatin. PFS
and OS, respectively, were 54% and 52% at 84 months. The
authors concluded that the impact of adjuvant ifosfamide
and cisplatin on survival outcomes was unclear, while pel-
vic relapses remained a concern [35]. In a recently pub-
lished retrospective analysis, 49 women with completely
resected stage I-IV CSs received in the adjuvant setting
either platinum-based chemotherapy with or without radi-
ation therapy (pelvic or WAI), or radiation therapy alone.
Three-year PFS for chemotherapy group (with or without
radiation therapy) was 35% versus 9% for radiation ther-
apy alone (HR = 1.74, p = 0.164), while the corresponding
3-year OS rates were 66% and 34%, respectively (HR =
2.02, p = 0.146). Interestingly, the majority of patients in
the chemotherapy group were treated with paclitaxel and
carboplatin [36]. When compared with other regimens, the
latter combination seems also to improve the overall sur-
vival rate of patients with ovarian CSs [37].
Endocrine therapy
In contrast to ESS, endocrine therapy has no place in the
adjuvant treatment of CS. However, given that apparently
30% of these tumours express estrogen and/or progester-
one receptors, hormone therapy may represent an option
in chemotherapy pretreated patients with hormone recep-
tor positive tumours [12].
Leiomyosarcomas (LMSs)
Epidemiology and Tumour Features
Smooth muscle cell tumours may be divided into three
groups: benign (leiomyoma), malignant (leiomyosar-
coma), and tumours of unknown malignant potential
[38]. Uterine LMS is a rare tumour, accounting for approx-
imately 1% of all uterine malignancies, and represents the
second more common uterine sarcoma. According to an
analysis of SEER program data, CS were the most com-
mon uterine sarcoma followed by LMS [3,12,39]. The
incidence of LMS in patients operated for presumed leio-
myoma is approximately 0.1–0.3% [40]. Unfortunately,
due to the stromal rather than endometrial origin of the
tumour, LMS is not often diagnosed preoperatively.
Although some patients complain of pain or bleeding and
undergo endometrial biopsy as a result of these symp-
toms, most women with LMS lack symptoms, while oth-
ers present with a rapidly enlarging pelvic mass and thus
do not undergo biopsy before surgery [12,16,17].
Sixty percent of women with LMS present with disease
clinically limited to the uterus. Cure rates for these
patients range from 20% to 60%, with rates depending on
the success of primary resection [12,13]. The recurrence
rate is approximately 70% for stage I and II disease, and
the site of recurrence is often distant [12,18]. Favourable
prognostic features to emerge in some studies include pre-
menopausal status, low mitotic count, pushing margins,
hyalinization, absence of necrosis, origin in a uterine lei-
omyoma, and tumour stage. However other studies ques-
tion these findings [18,41-43]. The main criteria used to
determine treatment and prognosis are: necrosis, nuclear
atypia, and mitotic count [12,41,43].
Surgical Treatment
Management practice varies for uterine LMS, and is poorly
supported by evidence in the current literature, but total
abdominal hysterectomy and bilateral salpingo-
oophorectomy is considered to be the standard surgical
treatment [4,12,13,16,44]. Contrary to CS, pelvic and/or
para-aortic lymphadenectomy is not indicated for LMS,
unless macroscopic extra-uterine disease is present; due to
the low rates of negative nodes and the fact that the dom-
inant pattern of recurrence in LMS is outside the pelvis
and the abdominal cavity [13,16,17,44].
Ovarian preservation may be considered in premenopau-
sal patients with early-stage leiomyosarcoma of the uterus
as case-control investigations suggest that it does not
adversely affect survival [13,44]. In a retrospective review
of 208 patients with LMS of the uterine, the multivariate
analysis showed that oophorectomy was associated with a
significantly worse disease-specific survival [44].World Journal of Surgical Oncology 2009, 7:38 http://www.wjso.com/content/7/1/38
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Radiation therapy
Pelvic radiation therapy has been used for adjuvant treat-
ment of uterine LMS. However, although radiation ther-
apy has been shown to reduce the pelvic relapse rate by
50%, studies have not demonstrated a significant survival
benefit with this approach [12,27,31,44-46]. The results
of the protocol 55874 coincide with this observation. This
significant randomized trial demonstrated that patients
with LMS did not show the same benefit from radiation as
patients with CSs [34].
In patients with LMS, in contrast to patients with other
uterine sarcomas, the dominant pattern of recurrence is
outside the pelvis and abdominal cavity [47-49]. At least
two thirds of patients with uterine LMS have some com-
ponent of distant disease at first recurrence. Thus,
although the rate of recurrence in the pelvis is not insub-
stantial, little is potentially gained by delivering pelvic
radiation as a postoperative adjuvant treatment.
Chemotherapy
No adjuvant treatment has been shown to improve sur-
vival, although prospective data are very limited. How-
ever, in a small phase II study, four cycles of adjuvant
chemotherapy with gemcitabine and docetaxel in patients
with completely resected stage I-IV, high-grade uterine
LMSs resulted in 2-year PFS rates that appear superior to
historical rates (this issue will be discussed more detailed
in the final section of the article) [50].
Endocrine therapy
Endocrine therapy has no place in the adjuvant treatment
of patients with LMS.
Endometrial Stromal Sarcoma (ESSs)
Epidemiology and Tumour Features
ESS is a rare entity of uterine malignancy, accounting for
0.2–1% of all uterine malignancies and 6–20% of all uter-
ine sarcomas [51-53]. Due to its rarity, ESS has only been
reported in a few studies, and these were limited to case
reports or retrospective analysis based on a small number
of patients. These tumours are most commonly seen in
premenopausal women, but age at presentation may
range from 20 to 80 years [12]. Patients typically present
with bleeding and pain [17,54]. Due to the fact that most
patients with ESS have obvious symptoms, they are usu-
ally diagnosed at an early stage [54-56].
According to its pathological features ESS has been classi-
fied as low grade or high grade [12,55]. Low-grade ESS is
characterized by fewer than 10 mitoses per 10 high-power
fields and a lack of significant atypia and often expresses
estrogen and progesterone receptors. It should be noted
that nowadays, rather than including high-grade ESSs in
the category of ESSs, they are grouped together with high-
grade or undifferentiated uterine sarcomas (UUSs). This is
important because the low-grade and high-grade variants
have vastly different prognostic factors and therapeutic
options [54-56].
ESS may arise from uterine stroma, adenomyosis, or pos-
sibly endometriosis [12,57]. They usually have an indo-
lent clinical course with 5-year survival rates of 80% to
almost 100%, but about 37–60% of patients eventually
recur after a very long time and 15–25% die of the disease
[13]. In ESS recurrences are usually local, but late recur-
rences may involve the lung and abdomen. Stage at pres-
entation is the best predictor of recurrence risk [12].
ESSs frequently show positive immunoreactivity for ER
and PR, which helps in differential diagnosis [57-68].
Reich et al [63], analysed ER and PR expression in a retro-
spective series of 21 patients with ESS. ER and PR were
measured with monoclonal antibodies and the peroxi-
dase-antiperoxidase method and a score was calculated, as
for breast carcinoma, based on both the percentage of
positive tumour cell nuclei and the staining intensity. The
authors concluded that ER and PR expression in ESSs is
heterogeneous. This finding may have implications for
hormone therapy in the management of these tumours
and may suggest that ER and PR should be routinely
quantified in ESSs by immunohistochemical methods.
Chu et al [62] evaluated the expression of ER-alpha and
ER-beta in low grade ESS and they suggested that loss of
ERβ expression may be a marker for malignancy. Accord-
ingly, Balleine et al [59] showed that PR isoform expres-
sion, similarly to that of a normal endometrial stroma, is
consistent with the highly differentiated phenotype of this
tumor and that variant differentiation or disease recur-
rence was accompanied by an altered PR isoform profile
that could impact on hormone response.
Surgical Treatment
Surgical treatment of ESS typically includes an exploratory
laparotomy, total abdominal hysterectomy and bilateral
salpingo-oophorectomy, omental biopsy, and aspiration
of abdominal fluid for cytologic evaluation
[7,12,13,54,69,70]. If the tumour is palpable in the para-
metrium, a more extensive procedure, such as a radical
hysterectomy, should be performed [12]. Lymph node
sampling is not the standard of care, as nodal involvement
by low-grade ESS is supposed to be rare [12]. In two
recently published series nodal involvement was found in
33–45% of cases during primary or secondary surgical
treatment, and lymphadenectomy has been suggested by
the authors as part of the surgical treatment [71,72]. How-
ever, this finding was observed in patients with more
advanced disease and, therefore, the role of lymphadenec-
tomy in early stages still remains controversial. Ovarian
ablation is necessary, as part of primary treatment,
because estrogens may act as a trophic agent for these
tumours [73].World Journal of Surgical Oncology 2009, 7:38 http://www.wjso.com/content/7/1/38
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Radiation therapy
Adjuvant radiation therapy is effective treatment for
patients with ESS due to excellent local control in all
stages and good disease-specific survival in early stages
[69,70]. Adjuvant radiation therapy clearly reduces the
incidence of pelvic recurrence; however, in the majority of
the studies conducted it has no effect on OS [70,74-77].
Chemotherapy
See the final section of this review.
Endocrine therapy
Low-grade endometrial stromal sarcomas are estrogen and
progesterone receptor positive tumors [63,78]. In the past,
hormonal therapy consisted of progestins for advanced,
recurrent or metastatic low-grade ESS. Medroxyprogesterone
acetate (MPA) and megestrole acetate are synthetic deriva-
tives of progesterone that exert their activity after binding to
the progesterone receptor [79]. Aromatase inhibitors [80-
83] and GnRH analogues [84-86] have become new effec-
tive alternatives for first and second line treatment. The high
recurrence rates after short disease free intervals in low-grade
ESS patients were partly due to inadvertent growth stimula-
tion during estrogen-containing hormone replacement ther-
apy and tamoxifen treatment, which are contraindicated
[73,78,87]. Recently, hormonal therapy has been intro-
duced for the prevention of recurrences. However, it should
be noted that well controlled randomised studies on ESSs
have not been conducted and the majority of the results
reported are based on small series.
Undifferentiated Uterine Sarcomas (UUSs)
Epidemiology and Tumour Features
Undifferentiated uterine sarcomas are high-grade epithe-
lioid or spindle cell sarcomas that cannot be classified
into one of the standard categories [4,13,35]. These
tumours usually present with abdominal or pelvic pain in
postmenopausal women and represent less than 5% of all
uterine sarcomas [12]. They are characterized by an
aggressive clinical behaviour, with a tendency to frequent
and early recurrences and with 5-year survival rates of 25–
55% [7,13,52]. Necrosis is a common finding [12,52].
The stage at diagnosis as well as the mitotic index have
emerged in some studies as the most significant predictor
of prognosis [12,52], a finding that has not been reported
in other series [88].
Surgical Treatment
The treatment of choice for undifferentiated uterine sarco-
mas is total abdominal hysterectomy and bilateral salp-
ingo-oophorectomy [12,13,17,19,24]. There are no data
in the literature to support or challenge lymph node dis-
section. While Gaducci et al [13] suggest that this surgical
procedure is not advisable, Ramondetta et al [12] recom-
mend lymph node dissection in order to determine the
risk of recurrence.
Radiation therapy
Radiation therapy is typically recommended for stage I
and II UUSs [12,13,30]. However, concern regarding dis-
tant recurrences has led to the consideration of combining
irradiation with chemotherapy.
Endocrine therapy
Hormonal therapy plays no role for UUSs due to the lack
of steroid receptor expression.
Overview of adjuvant chemotherapy in early 
stage uterine sarcomas
Older non-platinum containing regimens
The high incidence of distal metastasis in uterine sarcomas
makes adjuvant chemotherapy an appealing option.
Although adjuvant chemotherapy has been studied in a
number of trials, considerable controversy still surrounds
its use. The question is whether or not adjuvant chemother-
apy can achieve a significant increase in disease-free and
overall survival without major treatment-related toxicity. It
should be noted, that due to the rarity of uterine sarcomas,
very few prospective randomized studies have been con-
ducted. Also, the non randomised clinical-trial reports
often include a broad range of histological subtypes, which
restricts interpretation and application of results.
The role of adjuvant chemotherapy and its type still
remains unclear even for adult soft tissue sarcomas (STSs).
The EORTC randomised patients with completely resected
STSs to receive either the CyVADIC regimen (cyclophos-
phamide, vincristine, doxorubicin and dacarbazine) adju-
vantly or no additional treatment [89]. With a median
follow-up duration of 80 months, the 7-year relapse-free
survival was higher and the local recurrence rate lower in
the chemotherapy arm. Overall survival and the rates of
distant metastases were not affected by chemotherapy. In
contrast, in another randomized trial, Frustaci et al [90]
demonstrated that 5 cycles of adjuvant chemotherapy
with epirubicin and ifosfamide) significantly improved
median disease-free (48 months versus 16 months, p =
0.04) and overall survival (75 months versus 46 months,
p = 0.03) in patients with high-risk extremity STSs. An
update of the study showed the 5-year overall survival esti-
mate to be 66% and 46% (p = 0.04) for the chemotherapy
and control arm, respectively [91]. The Cochrane Review
performed a meta-analysis of 14 trials of adjuvant chemo-
therapy, involving 1568 patients with STSs. According to
this meta-analysis chemotherapy improved the local
recurrence-free interval (HR = 0.73), distant recurrence-
free interval (HR = 0.70), and overall recurrence-free inter-
val (HR = 0.75). The doxorubicin-based therapy yielded
an advantage in terms of overall survival, but failed to
achieve statistical significance (HR = 0.89) [92].
Although uterine sarcomas are different from STSs of the
trunk and extremities, in terms of pathogenesis and biolog-World Journal of Surgical Oncology 2009, 7:38 http://www.wjso.com/content/7/1/38
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ical behavior, and results of adjuvant chemotherapy in
early stage STSs cannot be extrapolated in uterine sarcomas,
some studies used either the VAC or the CyVADIC combi-
nation in the adjuvant setting. More specifically, in a retro-
spective analysis of stage I and II uterine sarcomas,
Buschbaum et al [93] reported recurrent disease in 37% of
patients who received adjuvant chemotherapy with the vin-
cristine, dactinomycin and cyclophosphamide (VAC) regi-
men. In another study, Hannigan et al [94] retrospectively
analyzed the outcome of patients who received after hyster-
ectomy and radiotherapy VAC regimen or the combination
of vincristine, doxorubicin and cyclophosphamide and
concluded that neither the probability of survival nor the
disease-free interval was improved by the addition of adju-
vant chemotherapy. Adjuvant VAC was also utilized in a
prospective, pilot study in patients with stage I uterine sar-
comas. The authors reported that recurrence rate was signif-
icantly (p < 0.02) less than that for patients treated by
surgery alone or by surgery plus radiation [95].
The impact of adjuvant CyVADIC on survival outcomes of
patients with stage I uterine sarcomas was examined in
two small prospective studies. Hempling et al [96], treated
twenty women who underwent total abdominal hysterec-
tomy and bilateral salpingo-oophorectomy with this
multiagent chemotherapy regimen, but failed to show a
significant impact on long-term survival in this group of
patients. Progression-free survival for the entire popula-
tion at 2 years was 80% and at 5 years 65%, while recur-
rence rates for pure sarcomas and carcinosarcomas did not
differ significantly. In a more recently published study,
Odunsi et al [97] reported results on adjuvant CyVADIC
in 24 patients with a very long duration of follow-up. The
estimated survival rate for the whole group was 88, 75,
and 69% at 2, 5, and 15 years, respectively. Factors that
did not affect survival included age, histology, and tumor
grade. Based on their data, the authors suggested that
CyVADIC may have a potential role in the adjuvant treat-
ment of early-stage uterine sarcoma.
Ifosfamide-containing regimens
Ifosfamide-based chemotherapy has been investigated in
the adjuvant setting in three prospective, non-randomized
trials. Kushner et al [98], treated patients with completely
resected moderate-to-high grade uterine sarcomas with
three cycles of adjuvant ifosfamide (1.5 g/m2/day × 3 con-
secutive days, repeated every 4 weeks). Median progres-
sion-free survival was 26 months with a corresponding 2-
year rate of 60%. The 2-year overall survival rate was
100%, dropping to 64% at three years. In another French
study conducted by Pautier et al [99], patients received
three cycles of adjuvant chemotherapy with doxorubicin,
cisplatin and ifosfamide (API) followed by radiotherapy.
When compared to a group of patients treated with adju-
vant radiotherapy alone, the 3-year disease-free survival
was 43% in the radiotherapy group and 76% in the com-
bined modality group. Of note, the two previously men-
tioned studies included a mixture of different histological
types. On the contrary, only patients with CS were
included in a prospective phase II GOG study, which uti-
lized the combination of ifosfamide and cisplatin for
stage I+II disease. Ifosfamide was administered 1.5 g/m2,
intravenously over 1 h, and cisplatin was given 20 mg/m2
followed by ifosfamide 1.5 g/m2/24 h as a continuous
infusion (daily × 5, every 21 days, × 3 cycles). PFS and OS,
respectively, were 69% and 82% at 24 months, and 54%
Table 1: Summary of studies on adjuvant chemotherapy in early-stage uterine sarcomas.
Study No of patients Radiation Regimens Recurrence (%) at 5 
years
5-year survival (%)
Buchsbaum et al, 1979 [94] 8 NR VAC 37 63
Omura et al, 1985 [100] 64 No DOX 39 53
van Nagel et al, 1986 [95] 7 No VAC 29 86
Berchuck et al, 1988 [6] 12 LMS Yes Various 83 42
Piver et al, 1988 [105] 11 No CyVADIC 18 89
Hempling et al, 1995 [96] 20 No CyVADIC 35 68
Resnik et al, 1995 [101] 23 CS No Etoposide + cisplatin + DOX 22 92 (at 2 years)
Gadducci et al, 1996 [43] 11 LMS 2 patients Various 39 NR
Sartori et al, 1997 [106] 5 CS No NR 40 NR
Chauveinc et al, 1999 [21] 24 Yes Various NR NR
Kushner et al, 2000 [98] 10 No IFO 50 67 (at 3 years)
Manolitsas et al, 2001 [102] 21 CS Yes various 9.5 95
Giuntoli et al, 2003 [44] 34 LMS 2 patients Various NR NR
Pautier et al, 2004 [99] 16 Yes API 28 100
Odunsi et al, 2004 [97] 24 No CyVADIC 33 75
Sutton et al, 2005 [35] 65 CS No IFO + Cisplatin 35 62
Ti et al, 2006 [104] 51 Yes various 59 67
Papadimitriou et al, 2007 [4] 31 12 patients Anthracycline-based 39 54
Wolfson et al, 2007 [33] 101 CS No CIM 52 46World Journal of Surgical Oncology 2009, 7:38 http://www.wjso.com/content/7/1/38
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and 52% at 84 months. Leukopenia was the most com-
monly reported, but manageable, toxicity. The authors
concluded that the impact of adjuvant ifosfamide and cis-
platin on survival outcomes was unclear, while pelvic
relapses remained a concern [35]. In contrast, in their ret-
rospective analysis of 31 patients with stage I or II uterine
sarcomas of various histologies, Papadimitriou et al [4]
found that adjuvant ifosfamide-containing chemotherapy
resulted in statistically longer OS when compared with
non-ifosfamide-containing chemotherapy.
The combination of ifosfamide (with MESNA uroprotection)
and cisplatin (CIM regimen) was also used in a randomized
phase III GOG study that enrolled 232 patients. This trial was
designed to compare patient outcome following adjuvant
treatment with WAI versus chemotherapy with three cycles of
CIM in women with completely resected CSs. Adjusting for
stage and age, the recurrence rate was 21% lower for CIM
patients than for WAI patients (relative hazard = 0.789, p =
0.245). The estimated death rate was 29% lower among the
CIM group (relative hazard = 0.712, p = 0.085) [33].
Anthracycline-based chemotherapy
The role of adjuvant doxorubicin has been examined in a
randomized GOG trial. After hysterectomy, 156 evaluable
patients with stage I or stage II uterine sarcomas were ran-
domly assigned to chemotherapy with doxorubicin for six
months or to no further treatment. Pelvic irradiation
(external or intracavitary) was optional before randomi-
zation. Of 75 patients receiving doxorubicin, 31 have suf-
fered recurrences compared with 43 of 81 receiving no
adjuvant chemotherapy, but this difference was not statis-
tically significant. Moreover, there was no difference in
progression-free interval or survival. The optional radio-
therapy did not influence the outcome although there was
a suggestion that vaginal recurrence was decreased by pel-
vic radiotherapy. The recurrence rates in specific histolo-
gies were not significantly different [100].
Anthracycline-based combinations have been used in CSs.
In a phase II trial, 42 consecutive patients were treated with
a combination containing etoposide 100 mg/m2, on days 1
and 2, cisplatin 50 mg/m2 on day 1, and doxorubicin 50
mg/m2 on day 1, repeated every 28 days. There were 23
patients with early-stage disease and 19 patients with
advanced or recurrent disease. Among patients with stages
I and II there were 5 (22%) recurrences and the 2-year over-
all survival rate was 92% [101]. Additionally, a sequential
approach with adjuvant radiation therapy and chemother-
apy has been correlated with improved clinical outcome. In
a pilot study, conducted by Manolitsas et al [102], patients
with stage I or II uterine CSs received after surgery tailored
radiation therapy and chemotherapy, consisting of cispla-
tin and epirubicin. The survival rate for those patients who
completed treatment according to the multimodality pro-
tocol was 95%, with a disease-free survival rate of 90%.
Newer agents and combinations
The combination of gemcitabine and docetaxel has
shown promising results as adjuvant chemotherapy for
completely resected stages I-IV high grade uterine LMSs.
As previously mentioned, Hensley et al [50] treated 25
patients with gemcitabine 900 mg/m2, on days 1 and 8,
plus docetaxel 75 mg/m2, on day 8, every 3 weeks for 4
cycles. With a median follow-up of 49 months for all
patients, 10 (45%) remained progression-free at 2 years,
with a median progression-free survival of 13 months.
Among the 18 patients with stages I or II disease, 59%
remained progression-free at 2 years, with a median pro-
gression-free survival of 39 months. Median overall sur-
vival for these patients was not yet reached.
Another combination that merits further evaluation in the
adjuvant setting, especially for patients with CSs, is the
paclitaxel and carboplatin doublet. In a retrospective anal-
ysis, 49 women with completely resected stage I-IV CSs
received adjuvantly either platinum-based chemotherapy
(primarily paclitaxel and carboplatin) with or without
radiation therapy or radiation therapy alone. Three-year
PFS for chemotherapy group (with or without radiation
therapy) was 35% versus 9% for radiation therapy alone,
while the corresponding 3-year OS rates were 66% and
34%, respectively (HR = 2.02, p = 0.146) [36]. Further-
more, in a retrospective analysis of 26 patients with ovar-
ian CSs, there was a trend for increased median survival
for those who were treated with the paclitaxel and carbo-
platin combination (p = 0.066) [37].
More recently, trabectedin, an agent that binds to the
DNA minor groove and has an original mechanism of
action involving proteins of the nucleotide excision repair
machinery has shown promising activity in patients with
advanced STSs. Several trabectedin-based combinations
have been tested in phase I trials, including combination
with cisplatin, paclitaxel, docetaxel and pegylated doxoru-
bicin [103]. Based on biological and/or histological fea-
tures, trabectedin will be possibly utilized in the adjuvant
setting in STSs, including uterine sarcomas.
The main studies conducted on adjuvant setting of early
stage uterine sarcomas are presented in Table
1[4,6,21,33,35,43,44,94-102,104-106].
Conclusion
Uterine sarcomas represent a heterogeneous group of rare
tumours that usually have an aggressive clinical behaviour
and a poor prognosis. Newer classifications will help to
distinguish the different types as we now recognise that
carcinosarcomas are most likely to be of epithelial origin.
The rarity of uterine sarcomas and their aggressive clinical
course has resulted in a relatively limited amount of liter-
ature. Total abdominal hysterectomy and bilateral salp-
ingo-oophorectomy remains the standard surgical care.World Journal of Surgical Oncology 2009, 7:38 http://www.wjso.com/content/7/1/38
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Lymph node dissection is indicated for carcinosarcomas
given their high incidence of lymph node metastases.
Some recent data on small numbers of patients with low-
grade endometrial stromal sarcomas appear to show an
incidence of nodal involvement higher than previously
expected, thus suggesting a role for lymphadenectomy.
Adjuvant pelvic radiotherapy appears to improve local
control without any significant impact on overall survival.
Regarding adjuvant chemotherapy, there is little evidence
in the literature supporting its use except for carcinosarco-
mas. However, more trials are needed to address these
issues, especially, their sequential application. Based on
some recent, albeit limited data, combinations such as
paclitaxel and carboplatin in carcinosarcomas, as well as
gemcitabine and docetaxel in leiomyosarcomas merit fur-
ther evaluation in prospective trials of adjuvant treatment.
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